Theravance Biopharma Inc
NASDAQ:TBPH
Intrinsic Value
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. [ Read More ]
The intrinsic value of one TBPH stock under the Base Case scenario is 14.41 USD. Compared to the current market price of 9.01 USD, Theravance Biopharma Inc is Undervalued by 37%.
Valuation Backtest
Theravance Biopharma Inc
Run backtest to discover the historical profit from buying and selling TBPH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Theravance Biopharma Signals Growth and Profits
2023-Q4 Earnings Call
Theravance Biopharma reported a productive 2023, increasing YUPELRI net sales 9% to $221 million and growing hospital volumes 46%. The company achieved non-GAAP profitability in Q4 and completed a $325 million capital return program. They are on track with the CYPRESS study for ampreloxetine and expect regulatory submission in China for YUPELRI midyear, aiming for greater market share. For 2024, a non-GAAP loss is anticipated in H1 due to seasonal drops in sales and increased R&D spend, with a return to breakeven expected in H2. A $25 million or $50 million TRELEGY milestone is possible, and limited cash burn is projected, with significant milestones anticipated to generate net cash before CYPRESS results in 2025.
Balance Sheet Decomposition
Theravance Biopharma Inc
Current Assets | 133.5m |
Cash & Short-Term Investments | 102.4m |
Receivables | 17.5m |
Other Current Assets | 13.6m |
Non-Current Assets | 248.5m |
PP&E | 45.4m |
Other Non-Current Assets | 203.1m |
Current Liabilities | 24.8m |
Other Current Liabilities | 24.8m |
Non-Current Liabilities | 144.2m |
Other Non-Current Liabilities | 144.2m |
Earnings Waterfall
Theravance Biopharma Inc
Revenue
|
57.4m
USD
|
Operating Expenses
|
-110.7m
USD
|
Operating Income
|
-53.3m
USD
|
Other Expenses
|
-1.9m
USD
|
Net Income
|
-55.2m
USD
|
Free Cash Flow Analysis
Theravance Biopharma Inc
What is Free Cash Flow?
TBPH Profitability Score
Profitability Due Diligence
Theravance Biopharma Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Theravance Biopharma Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
TBPH Solvency Score
Solvency Due Diligence
Theravance Biopharma Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Theravance Biopharma Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TBPH Price Targets Summary
Theravance Biopharma Inc
According to Wall Street analysts, the average 1-year price target for TBPH is 14.28 USD with a low forecast of 10.1 USD and a high forecast of 21 USD.
Ownership
TBPH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
TBPH Price
Theravance Biopharma Inc
Average Annual Return | -15.39% |
Standard Deviation of Annual Returns | 17.94% |
Max Drawdown | -78% |
Market Capitalization | 448.7m USD |
Shares Outstanding | 48 164 700 |
Percentage of Shares Shorted | 42.77% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 158 full-time employees. The company went IPO on 2014-05-16. The firm develops transformational medicines to improve the lives of patients suffering from serious illnesses. The firm's research is focused in the areas of inflammation and immunology. The company applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The firm is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.
Contact
IPO
Employees
Officers
The intrinsic value of one TBPH stock under the Base Case scenario is 14.41 USD.
Compared to the current market price of 9.01 USD, Theravance Biopharma Inc is Undervalued by 37%.